Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2007
01/25/2007US20070020218 Composition and method for the treatment of psoriasis
01/25/2007US20070020206 Use of biotin or a biotin derivative for lightening skin and treating age spots
01/25/2007US20070020199 Dispersible macromolecule compositions and methods for their preparation and use
01/25/2007US20070020198 inhalers used in the treatment of respiratory system disorders, such as chronic obstructive pulmonary disease and asthma
01/25/2007US20070020196 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
01/25/2007US20070020195 Nasally administered appetite suppressants
01/25/2007US20070020194 Nasally administered appetite suppressant
01/25/2007US20070020193 Dronabinol compositions and methods for using same
01/25/2007US20070020190 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
01/25/2007US20070020188 Pharmaceutical formulation containing irritant
01/25/2007US20070020187 Solid dosage formulations of narcotic drugs having improved buccal adsorption
01/25/2007US20070020186 Solid dosage formulations of narcotic drugs having improved buccal adsorption
01/25/2007US20070020182 Quaternary nitrogen heterocyclic boronic acid-containing compounds sensitive to glucose and fructose; contact lens; radiometers; kits; ophthalmic sensors
01/25/2007US20070017513 Method and apparatus for dispensing inhalator medicament
01/25/2007DE112005000178T5 Verfahren zur Herstellung von Rocuroniumbromid und Zwischenprodukte davon A process for preparing rocuronium bromide and intermediates thereof
01/25/2007DE102005034498A1 Orale Kontrazeption mit Trimegeston Oral contraception with Trimegestone
01/25/2007DE102005034267A1 New 4-chromenonyl-1,4-dihydropyridine derivatives, useful for treatment of e.g. aldosteronism, hypertension and cardiac insufficiency, are antagonists of the mineralcorticoid receptor
01/25/2007DE102005034266A1 New 8-dihydropyridyl-chromene derivatives, are antagonists of the mineralcorticoid receptor, useful for treatment and prevention of e.g. aldosteronism, hypertension and cardiac insufficiency
01/25/2007DE102005034265A1 New 4-pyrroloisoindolyl-substituted dihydropyridine derivatives, useful as antagonists of the mineralcorticoid receptor for treating e.g. aldosteronism, hypertension and stroke
01/25/2007DE102005034263A1 New 8-dihydropyridyl-chromene derivatives, useful for treatment and prevention of e.g. aldosteronism, hypertension and cardiac insufficiency, are antagonists of the mineralcorticoid receptor
01/25/2007DE102005034262A1 New N-phenyl pyridinecarboxamide derivatives, useful for the treatment and prevention of thrombotic disease, are inhibitors of plasminogen activator inhibitor-1
01/25/2007DE102005033954A1 Zusammensetzung, die eine liposomale Dispersion von SiO2-Nanopartikeln und ein ß-1,3-verknüpftes Glucanetherderivat umfasst A composition comprising a liposomal dispersion of SiO 2 nanoparticles and a .beta.-1,3-linked glucan ether derivative
01/25/2007DE102005033809A1 Composition, useful for activating growth hormones and strengthening the immune system, comprises amino acids and isotonic saline
01/25/2007DE102005033371A1 Substituierte Pyridocarboxamide Substituted Pyridocarboxamide
01/25/2007DE102005033103A1 Heterocyclylamid-substituierte Thiazole, Pyrrole und Thiophene Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes
01/25/2007DE102005033100B3 Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung New 1,4-benzothiazepine-1,1-Dioxidderivat with improved properties, these drug compound contained and processes for their preparation
01/25/2007DE102005032803A1 Gebrauchsfertige Mundwasserzusammensetzung und Verwendung derselben Ready to use mouthwash composition and use thereof
01/25/2007DE102005032625A1 Use of an agent comprising cocaine derivative and/or degradation product of the cocaine derivative, for the production of medicament to treat neural and neurodegenerative diseases e.g. dementia diseases, Parkinson diseases or depressions
01/25/2007DE102005031576A1 Use of benzoic acid, pyrimidine and benzamide compounds, as activators of soluble guanylate cyclase for the treatment or prevention of reperfusion injury,
01/25/2007CA2838108A1 Sustained release of antiinfectives
01/25/2007CA2658311A1 Cancer specific glycans and use thereof
01/25/2007CA2621010A1 Vegetation water composition for treatment of inflammatory skin conditions
01/25/2007CA2616146A1 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
01/25/2007CA2616141A1 Novel epilepsy treatment
01/25/2007CA2616129A1 Preparation of montelukast
01/25/2007CA2616091A1 Intermolecular association complex of a carrier and of an active principle
01/25/2007CA2616063A1 Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a receptor antagonists
01/25/2007CA2616031A1 Amino acid salts of rosiglitazone
01/25/2007CA2616008A1 Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
01/25/2007CA2615990A1 Enhanced ocular neuroprotection/neurostimulation
01/25/2007CA2615980A1 Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation
01/25/2007CA2615978A1 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
01/25/2007CA2615944A1 Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
01/25/2007CA2615860A1 Thiocolchicoside analogues with myorelaxant and anti-inflammatory activity
01/25/2007CA2615836A1 Lpa2 receptor agonist inhibitors of cftr
01/25/2007CA2615813A1 Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
01/25/2007CA2615795A1 Premature ovulation preventive agent
01/25/2007CA2615752A1 Use of thiazole derivatives and analogues in the treatment of cancer
01/25/2007CA2615751A1 N-(heteroaryl)-1-heteroarylalkyl-1h-indole-2-carboxamide derivatives, preparation and use thereof
01/25/2007CA2615744A1 Plexin d1 as a target for tumor diagnosis and therapy
01/25/2007CA2615741A1 Salt of fumaric acid and 3-(2-dimethylamino)methyl(cyclohex-1-yl))phenol and its crystalline forms
01/25/2007CA2615716A1 Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
01/25/2007CA2615676A1 N(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof
01/25/2007CA2615656A1 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
01/25/2007CA2615650A1 Novel piperidine derivatives
01/25/2007CA2615598A1 Compositions for treatment of systemic mastocytosis
01/25/2007CA2615596A1 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-oxadiazole-2-yl] phenyl) pyridine-3- sulphonamide
01/25/2007CA2615579A1 Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
01/25/2007CA2615552A1 Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent
01/25/2007CA2615533A1 Oral, rapidly disintegrating film, which cannot be spat out, for a neuroleptic
01/25/2007CA2615516A1 2-cyano-pyrimidines and -triazines as cysteine protease inhibitors
01/25/2007CA2615496A1 Medicaments containing famotidine and ibuprofen and administration of same
01/25/2007CA2615455A1 Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
01/25/2007CA2615447A1 Substituted amides, their preparation and their use as pharmaceuticals
01/25/2007CA2615444A1 Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
01/25/2007CA2615434A1 Perfluoroalkyl-containing complexes, process for their production as well as their use
01/25/2007CA2615433A1 Pyrazolo[1.5-a]pyrimidin-7-yl amine derivatives as protein kinase inhibitors
01/25/2007CA2615427A1 Oral contraception with trimegestone
01/25/2007CA2615426A1 Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
01/25/2007CA2615420A1 2-arylbenzothiazoles and uses thereof
01/25/2007CA2615403A1 Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
01/25/2007CA2615380A1 Quinazoline derivatives useful in cancer treatment
01/25/2007CA2615378A1 Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
01/25/2007CA2615374A1 Treatment of cancer
01/25/2007CA2615373A1 Quinazoline derivatives useful in cancer treatment
01/25/2007CA2615362A1 Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
01/25/2007CA2615356A1 Homogemcitabines
01/25/2007CA2615254A1 Combinations of pyrimidylaminobenzamide bcr-abl inhibitors and mtor inhibitors for the treatment of leukemia
01/25/2007CA2615236A1 Substituted piperidine derivatives as somatostatin sst1 receptor antagonists
01/25/2007CA2615231A1 Prevention and treatment of ophthalmic complications of diabetes
01/25/2007CA2615112A1 Synthesis and complete stereochemical assignment of psymberin/irciniastatin for anti-tumor use
01/25/2007CA2615105A1 Histone deacetylase inhibitors
01/25/2007CA2615051A1 Use of soluble guanylate cyclase for the treatment of raynaud's phenomenon
01/25/2007CA2615049A1 Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes
01/25/2007CA2615045A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
01/25/2007CA2614988A1 Breath freshening and oral cleansing product comprising a magnolia bark extract and surfactant
01/25/2007CA2614963A1 Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
01/25/2007CA2614939A1 Phenyl substituted piperazine-derivatives as inhibitors of plaminogenic activator inhibitors-i (pai-i)
01/25/2007CA2614850A1 Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
01/25/2007CA2614846A1 Acne treatment
01/25/2007CA2614770A1 The use of inhibitors of histone deacetylases in combination with compounds acting as nsaid for the therapy of human diseases
01/25/2007CA2614764A1 Sustained release of antiinfectives
01/25/2007CA2614697A1 Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
01/25/2007CA2614687A1 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
01/25/2007CA2614677A1 Methods for treating and diagnosing complications of premature birth
01/25/2007CA2614674A1 Antiviral compounds
01/25/2007CA2614585A1 Compounds for treatment of lipase-mediated diseases
01/25/2007CA2614524A1 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic
01/25/2007CA2614468A1 Novel granulation process and granulate produced therefrom
01/25/2007CA2614401A1 Novel heteroaryl fused cyclic amines